Jeong Y - Search Results

1

A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway.

Li GY, Jung KH, Lee H, Son MK, Seo J, Hong SW, Jeong Y, Hong S, Hong SS. Li GY, et al. Among authors: jeong y. Cancer Lett. 2013 Feb 1;329(1):59-67. doi: 10.1016/j.canlet.2012.10.013. Epub 2012 Oct 17. Cancer Lett. 2013. PMID: 23085493

2

A novel imidazopyridine analogue as a phosphatidylinositol 3-kinase inhibitor against human breast cancer.

Lee H, Li GY, Jeong Y, Jung KH, Lee JH, Ham K, Hong S, Hong SS. Lee H, et al. Among authors: jeong y. Cancer Lett. 2012 May 1;318(1):68-75. doi: 10.1016/j.canlet.2011.12.001. Epub 2011 Dec 8. Cancer Lett. 2012. PMID: 22155744

3

Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.

Jung KH, Zheng HM, Jeong Y, Choi MJ, Lee H, Hong SW, Lee HS, Son MK, Lee S, Hong S, Hong SS. Jung KH, et al. Among authors: jeong y. Cancer Lett. 2013 Jan 1;328(1):176-87. doi: 10.1016/j.canlet.2012.08.005. Epub 2012 Aug 15. Cancer Lett. 2013. PMID: 22902995

4

HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis.

Lee H, Jung KH, Jeong Y, Hong S, Hong SS. Lee H, et al. Among authors: jeong y. Cancer Lett. 2013 Jan 1;328(1):152-9. doi: 10.1016/j.canlet.2012.08.020. Epub 2012 Aug 26. Cancer Lett. 2013. PMID: 22929971

5

IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.

Lee JH, Lee H, Yun SM, Jung KH, Jeong Y, Yan HH, Hong S, Hong SS. Lee JH, et al. Among authors: jeong y. Cancer Lett. 2013 Feb 1;329(1):99-108. doi: 10.1016/j.canlet.2012.10.028. Epub 2012 Nov 8. Cancer Lett. 2013. PMID: 23142281

6

Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis.

Kim O, Jeong Y, Lee H, Hong SS, Hong S. Kim O, et al. Among authors: jeong y. J Med Chem. 2011 Apr 14;54(7):2455-66. doi: 10.1021/jm101582z. Epub 2011 Mar 9. J Med Chem. 2011. PMID: 21388141

7

Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors.

Park H, Jeong Y, Hong S. Park H, et al. Among authors: jeong y. Bioorg Med Chem Lett. 2012 Jan 15;22(2):1027-30. doi: 10.1016/j.bmcl.2011.11.124. Epub 2011 Dec 7. Bioorg Med Chem Lett. 2012. PMID: 22196123

8

Selectivity enhancement arising from interactions at the PI3K unique pocket.

Jeong Y, Lee J, Lee Y, Ham K, Choi S, Hong S. Jeong Y, et al. ChemMedChem. 2012 Aug;7(8):1379-83. doi: 10.1002/cmdc.201200245. Epub 2012 Jun 22. ChemMedChem. 2012. PMID: 22730062 No abstract available.

9

Selective and potent small-molecule inhibitors of PI3Ks.

Jeong Y, Kwon D, Hong S. Jeong Y, et al. Future Med Chem. 2014 May;6(7):737-56. doi: 10.4155/fmc.14.28. Future Med Chem. 2014. PMID: 24941870 Review.

10

Discovery of wrightiadione as a novel template for the TrkA kinase inhibitors.

Jeong Y, Lim SM, Hong S. Jeong Y, et al. Bioorg Med Chem Lett. 2015 Nov 15;25(22):5186-9. doi: 10.1016/j.bmcl.2015.09.070. Epub 2015 Sep 30. Bioorg Med Chem Lett. 2015. PMID: 26442778

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,115 results

Search Page

Filters